About E3 ubiquitin-protein transferase RMND5B
E3 ubiquitin-protein transferase RMND5B (RMND5B) is a protein
from Homo sapiens identified by UniProt accession
Q96G75, 393 residues long.
MolForge cross-references it against 0 known binders and
10 disease associations.
Target properties
| Protein name | E3 ubiquitin-protein transferase RMND5B |
| UniProt accession | Q96G75 |
| Gene | RMND5B |
| Organism | Homo sapiens |
| Length | 393 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (10)
Diseases linked to this target (Open Targets).
- dyskeratosis congenita · score 0.48
- esophageal squamous cell carcinoma · score 0.03
- neoplasm · score 0.01
- systemic juvenile idiopathic arthritis · score 0.01
- oral squamous cell carcinoma · score 0.01
- dysplasia · score 0.01
- calf circumference measurement · score 0.00
- colorectal adenocarcinoma · score 0.00
- cancer · score 0.00
- esophageal adenocarcinoma · score 0.00
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-Q96G75-F1 | alphafold | PREDICTED | 90.46 | — |
Amino-acid sequence (393 residues)
MEQCACVERE LDKVLQKFLT YGQHCERSLE ELLHYVGQLR AELASAALQG TPLSATLSLV MSQCCRKIKD TVQKLASDHK DIHSSVSRVG KAIDRNFDSE ICGVVSDAVW DAREQQQQIL QMAIVEHLYQ QGMLSVAEEL CQESTLNVDL DFKQPFLELN RILEALHEQD LGPALEWAVS HRQRLLELNS SLEFKLHRLH FIRLLAGGPA KQLEALSYAR HFQPFARLHQ REIQVMMGSL VYLRLGLEKS PYCHLLDSSH WAEICETFTR DACSLLGLSV ESPLSVSFAS GCVALPVLMN IKAVIEQRQC TGVWNHKDEL PIEIELGMKC WYHSVFACPI LRQQTSDSNP PIKLICGHVI SRDALNKLIN GGKLKCPYCP MEQNPADGKR IIF
Explore E3 ubiquitin-protein transferase RMND5B with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets